Detalhe da pesquisa
1.
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
Blood
; 132(25): 2629-2638, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30305280
2.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Haematol
; 11(1): e38-e50, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38065203
3.
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial.
EJHaem
; 4(3): 876-881, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37601870
4.
Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.
J Exp Med
; 219(11)2022 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053753
5.
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.
Blood Adv
; 4(2): 274-286, 2020 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31968078